"1.400 million Chinese man can not be a "do not clearly Changshan Pharmaceutical executives have cash in 80 million

Changshan Pharmaceutical operate this wave of God!  In the May 15 announcement that the Chinese men with erectile dysfunction (ED) patients about 1.400 million people a hot topic, after the stock soared the daily limit for two consecutive days (May 16, May 17 rose 9.6%), the company today (May 17) announced that the high SOAR High will Xia, Ding Jianwen, Huang Guosheng, etc. Today, four executives a total reduction of 1008 million shares, reducing the amount of over 87.64 million yuan。  According to 2017 Annual Report, tree Huawei Changshan Pharmaceutical Company's controlling shareholder, actual controller, and served as chairman and general manager, holds 36.41% of the shares of the company。As director Ding Jianwen, deputy general manager, Huang Guosheng, deputy general manager for the company, the high will Xia is one of the founders of the company。  Every time there was Xiao Bian noted that after the announcement caused heated discussion on social media, it Changshan Pharmaceutical stocks, many investors questioned said that a story is to Changshan Pharmaceutical executives pulled holdings。  It is worth noting that last October 28, Changshan Pharmaceutical's announcement that the controlling shareholder of the high Shuhua, director Chen Xi, director Ding Jianwen, senior management Huang Guosheng, senior management Zhiying proposed within ten on October 28, 2017 within six months fell by nearly 30 million shares after five days。Today is the last day of the six-month period。  Meanwhile, Changshan Pharmaceutical 17th night announcement that: the company's stock for two consecutive days (May 16, 2018, 17) closing price deviation from the cumulative value of more than 20%, according to the relevant provisions of the Shenzhen Stock Exchange, is case of abnormal fluctuations in stock。  Changshan Pharmaceutical said that although the company has now achieved a relevant approval documents required for the production of sildenafil citrate, but the product production, sales require a certain time and not immediately realize sales in the short term on the company results will not cause a significant impact。New products market size, market share and promote progress and may be lower than expected, future product sales have greater uncertainty。Current market sildenafil citrate manufacturers including Pfizer, Guangzhou Baiyun Mountain and Jiangsu Yabang, which Pfizer still holds the major market share。In addition, there are a number of domestic manufacturers ready to produce sildenafil citrate, the product of post-market competition intensified at risk。  In recent years has been to expand the "Viagra" business May 15 evening, Changshan Pharmaceutical (300 255.SZ) announced that its wholly-owned subsidiary of a treatment for ED tablet product obtained GMP certificate, the products can be marketed。The company said in a statement, 1.400 million Chinese people suffer from ED, broad market。    Public information, also known as sildenafil citrate, Viagra, Chinese referred to as "Viagra"。"Viagra" is the English transliteration of Viagra, a drug originally by the US Pfizer (Pfizer Company) pharmaceutical companies to develop and produce a treatment for angina。  In clinical trials, it was found that the effect of its general treatment of angina pectoris, but then treat impotence with special effects。This unexpected discovery prompted manufacturers to drug therapy altogether declaration of impotence。March 27, 1997, the US Food and Drug Administration (FDA) formally approved the drug as a dedicated drug treatment for impotence。  Since May 2014 Pfizer's Viagra patent expires in China, more than 20 domestic manufacturers have to fight domestic "Viagra" approval of generic drugs, hoping to win a share of the market。  Daily News reporter noted that in recent years, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (listed company that is Changshan Pharmaceutical) has been continuously expanding such products business。  May 2017, Changshan Pharmaceutical announced that for the good of sildenafil products preparatory work for listing, to better meet customer and market demand, decided to establish sildenafil sales division in the company's sales men, with overall responsibility for the West sildenafil product sales。  In October 2017, which said, Hebei Province received Food and Drug Administration issued a "drug GMP certificates", certifications range of pharmaceutical raw materials。Obtain the certificate, indicating Changshan Pharmaceutical sildenafil citrate raw material drug production quality management system in line with the "Good Manufacturing Practice", it can be formally put into production and on sale。  ▲ Changshan Pharmaceutical official website screenshot According to the latest announcement, the wholly owned subsidiary of Changshan medicine was "Drug GMP Certificate" certified workshop is a solid preparation workshop, the production of varieties of sildenafil citrate tablets。This means that, Changshan medicine can officially put into operation and sale of "Viagra" products, from raw material medicine "evolution" into a tablet。  (Note: the drug, by chemical synthesis, or a plant extract prepared biotechnologies powder used as the pharmaceutically acceptable, crystalline, extract and the like, the patient can not be taken directly, a substance needed for further processing; the formulation, such as tablets, capsules and the like, are under Pharmacopoeia standards pharmaceutical formulation prescribed norms, or extracts made after processing has a certain size, it can be used directly in the prophylactic treatment of a class of drugs。) Reporter Administration Food and Drug Administration official website to retrieve in the country "sildenafil citrate" found that the current total of 16 "Zhunzi" approval number of the product record, involving a total of 10 companies, pharmaceutical raw materials and dosage form is divided into different specifications of the tablet。  ▲ Source: National Food Drug Administration official website of the company relations point of view, Changshan Biochemical Pharmaceutical (Jiangsu) Co., Ltd. is a wholly owned subsidiary of Changshan medicine; Changzhou Yabang Pharmaceutical Co., Ltd. and Jiangsu Yabang Epson Pharmaceutical Ltd. belong to Jiangsu Yabang Pharmaceutical Group Co., Ltd. subsidiary。  1.400 million people suffer from ED, fly it?  Changshan Pharmaceutical said in a statement, according to statistics, the number of patients about domestic ED 1.400 million people, which assume 30% of the treatment, the number will reach 42 million, ED patients receiving treatment can assume multiple use drugs each year, the future of China's potential market size is expected to reach ten billion yuan level, the market is vast。  According to the National Bureau of Statistics published data show that the year 2016, the total number of male population of about 7.0800000000。If this is the case of the base, according to the statement Changshan medicine, almost every five men there is one person suffering from ED– this is not excluded in juvenile males。  Some users questioned the data in Shares。  In this regard, Daily Economic News reporters Jin Ri and Zhi Diangai Securities Department, the official said, the data from the State Securities two years ago。It said the company also saw a number of other data sources, generally are similar。For example, once disclosed Baiyun Mountain 1.2.7 billion people suffer from ED data, so the company believes 1.There are still 400 million data reliability。  Reporters combed found that in September 2017, a Dongxing Securities research reported, China 20-70 year old male in ED prevalence rate of about 26%, the number of patients 1.About 300 million。  ▲ Source: Dongxing Securities in February 2017, a Soochow Securities research reported on Baiyun Mountain, the number of ED patients in China about 1.2.7 billion。  ▲ Source: 2015 Soochow Securities, Ping An Securities in a research report claimed that the number of Chinese patients with ED 8000 million。  ▲ Source: Ping An Securities But others hold more conservative views。November 14, 2016, Guangsheng appear (300436.SZ) issued a bulletin to get sildenafil citrate clinical documents relating to point out, ED patients a conservative estimate, about 100 million people worldwide, of which the number of patients in China is about 20 million。